[go: up one dir, main page]

WO1999043361A8 - Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures - Google Patents

Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures

Info

Publication number
WO1999043361A8
WO1999043361A8 PCT/DK1999/000080 DK9900080W WO9943361A8 WO 1999043361 A8 WO1999043361 A8 WO 1999043361A8 DK 9900080 W DK9900080 W DK 9900080W WO 9943361 A8 WO9943361 A8 WO 9943361A8
Authority
WO
WIPO (PCT)
Prior art keywords
glp
helix
aggregates
derivatives
content exceeding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK1999/000080
Other languages
English (en)
Other versions
WO1999043361A1 (fr
Inventor
Liselotte Bjerre Knudsen
Per Olaf Huusfeldt
Per Franklin Nielsen
Niels C Kaarsholm
Helle Birk Olsen
Lars Thim
Soeren Erik Bjoern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to JP2000533156A priority Critical patent/JP2002504527A/ja
Priority to AU27128/99A priority patent/AU2712899A/en
Priority to EP99907325A priority patent/EP1060192A2/fr
Publication of WO1999043361A1 publication Critical patent/WO1999043361A1/fr
Publication of WO1999043361A8 publication Critical patent/WO1999043361A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention se rapporte à une composition pharmaceutique contenant un dérivé de GLP-2 (peptide de type glucagon 2) ayant une solubilité et/ou une stabilité améliorée(s), ainsi qu'à un procédé permettant d'améliorer la solubilité et/ou la stabilité du peptide GLP-2 ou d'un fragment ou d'un analogue de ce peptide.
PCT/DK1999/000080 1998-02-27 1999-02-25 Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures Ceased WO1999043361A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000533156A JP2002504527A (ja) 1998-02-27 1999-02-25 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
AU27128/99A AU2712899A (en) 1998-02-27 1999-02-25 Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
EP99907325A EP1060192A2 (fr) 1998-02-27 1999-02-25 Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK27198 1998-02-27
DK0271/98 1998-02-27

Publications (2)

Publication Number Publication Date
WO1999043361A1 WO1999043361A1 (fr) 1999-09-02
WO1999043361A8 true WO1999043361A8 (fr) 1999-10-14

Family

ID=8091669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000080 Ceased WO1999043361A1 (fr) 1998-02-27 1999-02-25 Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures

Country Status (4)

Country Link
EP (1) EP1060192A2 (fr)
JP (1) JP2002504527A (fr)
AU (1) AU2712899A (fr)
WO (1) WO1999043361A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DK1326630T3 (da) 2000-09-18 2008-09-15 Sanos Bioscience As Anvendelse af GLP-2-peptider
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
WO2004035624A2 (fr) * 2002-10-14 2004-04-29 Novo Nordisk A/S Composes glp-2, leurs formulations et leurs utilisations
CN1771080B (zh) 2003-04-08 2010-12-15 诺沃挪第克公司 包括至少一个色谱处理步骤的生产治疗用多肽或其前体的方法
WO2004089985A1 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Compositions pharmaceutiques stables
CN1812808B (zh) 2003-06-03 2012-07-04 诺沃挪第克公司 稳定化的药物肽组合物
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
BR122019021416A2 (fr) * 2003-09-19 2019-12-21
RU2401276C2 (ru) * 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
CN101380476A (zh) * 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
CA2585482C (fr) 2004-11-01 2018-01-02 Nps Allelix Corp. Traitement de patients atteints du syndrome de l'intestin court avec colon en continuite
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN101128214A (zh) 2005-03-18 2008-02-20 诺和诺德公司 长效glp-1化合物
WO2006097535A2 (fr) * 2005-03-18 2006-09-21 Novo Nordisk A/S Agonistes de peptides de la famille du glucagone presentant une activite similaire a la secretine
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
EP2280993A1 (fr) 2008-05-15 2011-02-09 Novo Nordisk A/S Purification de peptides préparés par synthèse en phase solide
JP5977945B2 (ja) 2008-08-06 2016-08-24 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有するコンジュゲートタンパク質
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
EP2461831B1 (fr) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Hormones de croissance ayant une efficacité in vivo prolongée
CA2787895A1 (fr) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Composes stables d'hormone de croissance
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN113710692A (zh) 2019-02-11 2021-11-26 Opko生物科学有限公司 长效glp-2类似物
WO2022157747A2 (fr) 2021-01-25 2022-07-28 Mylan Ireland Limited Compositions peptidiques pharmaceutiques et leurs procédés de préparation
NZ809455A (en) * 2021-09-10 2025-09-26 Zealand Pharma As Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110977A (en) * 1993-09-17 2000-06-29 Novo Nordisk As Human insulin derivative and pharmaceutical composition comprising it
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
CZ297338B6 (cs) * 1996-03-01 2006-11-15 Novo Nordisk A/S Peptid potlacující chut k jídlu, farmaceutický prostredek jej obsahující a jeho pouzití
EP1231219B1 (fr) * 1996-04-12 2010-08-25 1149336 Ontario Inc. Peptide-2 analogue au glucanon
WO1998008872A1 (fr) * 1996-08-30 1998-03-05 Novo Nordisk A/S Derives de glp-2

Also Published As

Publication number Publication date
JP2002504527A (ja) 2002-02-12
AU2712899A (en) 1999-09-15
WO1999043361A1 (fr) 1999-09-02
EP1060192A2 (fr) 2000-12-20

Similar Documents

Publication Publication Date Title
WO1999043361A8 (fr) Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures
AU2610799A (en) Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
HUP0003305A3 (en) Hiv protease inhibiting tetrahydro-pyrimid-2-on derivative, pharmaceutical compositions containing it and process for producing the compound
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
CA2370565A1 (fr) Compositions pharmaceutiques contenant de la vitamine d pour application cutanee
HUP0001285A3 (en) Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them
WO2001045678A3 (fr) Medicament, son procede de production et son utilisation
WO2000046069A3 (fr) Materiau generateur de gaz favorisant l'amorçage et procede correspondant
AU2001269198A1 (en) Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
AU2839801A (en) Aromas and aroma compositions containing 4,8-dimethyl-3,7-nonadien-2-one, and a method for the production thereof
AU3031797A (en) New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
HUP0204157A3 (en) 1,3-dihydro-2h-indol-2-one derivatives, process for preparation of the compounds and pharmaceutical compositions containing the same
MY127953A (en) Gabapentin-containing solid compositions and process for preparing the same
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
CA2343732A1 (fr) .delta.-lactones .gamma.-phenyl-substituees, leurs analogues, et leurs utilisations
AU2002218075A1 (en) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
ID27765A (id) Plester gel yang mengandung steroid dan proses pembuatannya
WO2001010408A3 (fr) Composition pharmaceutique aqueuse a base de moxifloxacine ou de ses sels
AU4134297A (en) 2,4-disubstituted pyrimidine derivatives, process for producing the same, and medicinal compositions containing the same
HUP9701660A3 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]pentadekanon derivatives, process for producing them, and pharmaceutical compositions containing them
IL129616A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
CA2296560A1 (fr) Derives d'acides amines pour le traitement des accidents cerebrovasculaires
HUT74615A (en) 2,3-cyclic-condensed-1,4-dihydro-pyridine derivatives, process for producing them and pharmaceutical compositions containing the same
HUP0204430A3 (en) Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives, the obtained new compounds and pharmaceutical compositions containing thereof
AU3825700A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999907325

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999907325

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999907325

Country of ref document: EP